HC Wainwright & Co. maintained its Xenetic Biosciences [XBIO] rating to the equivalent of Buy but changed the price target to $5.0 from $2, in a research note dated 2021-01-11. That figure represents around a 106.61% premium from where the company’s shares closed on Friday.
Is Xenetic Biosciences Inc. [NASDAQ:XBIO] a Good Buy Right Now?
It should be noted that XBIO technical indicators for short, intermediate as well as long term progress have placed an overall average of 100% as Buy. The average signal changed from 100% Buy in the last week and compares with 40% Buy in the past month. Data from Xenetic Biosciences Inc.’s Trend Spotter indicated that the signals were Strengthening. The stock current average is 1.53 million shares in the past 20 days and the short term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was 4.48 million shares while the medium term average advocated for 100% Buy. The average long-term signal stands at 100% Buy and the 100-day average volume stands at 2.34 million shares.
XBIO Price Performance
On Wall Street, Xenetic Biosciences Inc. [NASDAQ:XBIO] finished Friday’s session up 5.22% at $2.42. The stock went up to $2.43 at the same session while its lowest single day price was $2.24. In the last five days, it saw a rise of about 18.63%, Xenetic Biosciences Inc. shares gained by almost 18.63% since the beginning of the year. However, the share price has dropped to as low as -58.63% below its one year high. On 01/06/21, the company shares recorded $2.84, the highest single-day price it has got to in the last 52-weeks and a 52-week low was seen on 01/04/21, the same year at $2.00. The company’s shares have inclined by 50.31% in the past year. The 50-day SMA achieved is $1.43 while the 200-day SMA is $1.10. Volume dropped to 0.52 million from 0.74 million in the previous session.
XBIO Stock Support And Resistance Levels
On the 24-hour scale, the immediate backing is perceived around 2.30 level, and in case of violation of this particular level, it will cause more drop to 2.17 level. On the upper level, 2.55 is still the key resistance. The stock may increase to the subsequent resistance at 2.49. The Relative Strength Index (RSI) pinned on the 14-day chart is 64.47, implying a neutral technical stance while the MACD stands at 0.28, meaning price will decrease in the next trading period. Percent R indicator moved to 36.52%, implying low price movement. Stochastic %K at 60.00% suggest selling the stock.
What is the short interest in Xenetic Biosciences Inc.?
Short interest in the Xenetic Biosciences Inc. stock has surged, increasing by 50130.0 shares to total 0.53 million shares on Dec 14, 2020. The interest had seen shares on Nov 12, 2020 stand at 0.58 million, data from Yahoo Finance shows. The decrease of -9.49% suggests the stock saw some decreased bullish sentiment. The stock’s days to cover (short ratio) moved to while the shorted shares account for just 6.58% of the overall float for the stock.
Xenetic Biosciences Inc.’s Biggest Shareholders: Who Owns Xenetic Biosciences Inc. [XBIO]?
Filings by Renaissance Technologies LLC showed that the firm now holds a total of 59,209 shares or roughly 0.94% of the outstanding XBIO shares. This means their shares have reduced by -113,988 from the 59,209 the investor reportedly held in its prior 13-F filing. With the conclusion of the sale, Royal Bank of Canada updated stake is worth $30,770. The Morgan Stanley & Co. LLC’s holdings currently number 261 shares at $631.62. According to the firm’s last 13F report, Crewe Advisors, LLC shares in the company at filing stood at 115 shares, roughly $131.
XBIO Earnings Forecast For The Current Quarter
Xenetic Biosciences Inc. [XBIO] is expected to report weak earnings results for the quarter ending on Dec 2020. Consensus estimates give the company expected revenues of $130k and an earnings per share of -$0.23 for Dec 2020. The estimates represent upside of 117.10% and 59.30% in the company’s revenue and earnings per share, respectively, on a year-on-year basis.
XBIO Earnings Estimates For The Current Year
For the financial year, Xenetic Biosciences Inc. [NASDAQ:XBIO] is expected to bring in revenue of $410k. The returns are nearly $0.39 million higher than the company’s actual revenue recorded in the fiscal year 2019. In terms of EPS for the 2020, estimate put it at -1.67, higher than that of FY19 by $4.66. Estimates put this year’s earnings growth at 73.60%, 59.30% for the next. As for sales, forecasts are for an increase of 2,311.80% in the current fiscal year and a further 117.10% over the following year.